News MSD trims outlook as it aims to shave $3bn off costs MSD is embarking on a $3bn cost-reduction drive to prepare for the loss of patent protection for cancer blockbuster Keytruda.
News MSD adds rocket fuel to Winrevair's engine in PAH ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch
News MSD leaps on FDA approval of PAH drug sotatercept MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather th
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
